Use your browser's BACK button to return to your page of origin.
Comparative analysis of two commercial phenotypic assays for drug
susceptibility testing of human immunodeficiency virus type 1.
Journal of Clinical Microbiology 2002;40(1):31-35.
Quari SH, Respess R, Weinstock H, Beltrami E, Hertogs K, Larder BA,
Petropoulos CJ, Hellman N, Heneine W.
Abstract
Human immunodeficiency virus type 1 (HIV-1) isolates from 50 plasma specimens
were analyzed for phenotypic susceptibility to licensed reverse transcriptase
inhibitors and protease inhibitors by the Antivirogram and PhenoSense HIV
assays. Twenty of these specimens were from recently seroconverted drug-naive
persons, and 30 were from patients who were the sources of occupational exposures
to HIV-1; 16 of the specimens in the latter group were from drug-experienced
patients. The phenotypic results of the Antivirogram and PhenoSense HIV assays
were categorized as sensitive or reduced susceptibility on the basis of the
cutoff values established by the manufacturers of each assay. Data for 12
to 15 drugs were available by both assays for 38 specimens and represented
a total of 529 pairs of results. The two data sets had a 91.5% concordance
by phenotypic category. The discordant results (n = 45) were distributed
randomly among 26 specimens and included 28 results (62.2%) which were within
a twofold difference of the assay cutoff values. None of the discordant results
were associated with primary resistance mutations that predicted high-level
(>20-fold) resistance. Discordant results were distributed equally among
specimens from drug-experienced and drug-naive individuals and were slightly
higher for protease inhibitors than for nonnucleoside reverse transcriptase
inhibitors or nucleoside reverse transcriptase inhibitors. The findings of
the present study demonstrate that the results of the Antivirogram and PhenoSense
HIV assays correlate well, despite the use of different testing strategies.